ChemRxiv
These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
Preprint.pdf (1.37 MB)

Simeprevir and Eltrombopag as Potential Inhibitors of SARS-CoV2 Proteases: A Molecular Docking and Virtual Screening Approach to Combat COVID-19

preprint
submitted on 20.09.2020 and posted on 21.09.2020 by Ananta Swargiary, AKALESH Verma, Manita Daimari, Mritunjoy Kumar Roy
The present study investigates the binding affinities of 61 FDA approved drugs against two key proteases of SARS-COV2, 3-chymotrypsin-like protease and papain-like protease. We also investigated the ADMET properties of the top 10 best binding drugs to understand the druglikeness property.

Funding

The present study do not have any specific funding

History

Email Address of Submitting Author

ananbuzoo101@gmail.com

Institution

Bodoland University

Country

India

ORCID For Submitting Author

0000-0001-9594-3666

Declaration of Conflict of Interest

Author do not have any conflict of interest

Version Notes

Final draft

Exports

Logo branding

Exports